|
US5744500A
(en)
|
1990-01-03 |
1998-04-28 |
Teva Pharmaceutical Industries, Ltd. |
Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
|
|
IL118836A
(en)
*
|
1996-07-11 |
2001-01-11 |
Teva Pharma |
Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
|
|
JP2003512426A
(ja)
|
1999-10-27 |
2003-04-02 |
テバ ファーマシューティカル インダストリーズ リミティド |
双極性気分障害における躁病の治療のための１−アミノインダンの使用。
|
|
SI1567152T1
(sl)
*
|
2002-11-15 |
2013-10-30 |
Teva Pharmaceutical Industries Ltd. |
Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
|
|
GB2411355B
(en)
|
2004-02-27 |
2006-02-22 |
Niche Generics Ltd |
Pharmaceutical composition
|
|
US20060018957A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Lerner E I |
Pharmaceutical dosage forms including rasagiline
|
|
CA2587295A1
(en)
*
|
2004-11-10 |
2006-05-18 |
Teva Pharmaceutical Industries Ltd. |
Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
|
|
US8367105B2
(en)
|
2004-11-10 |
2013-02-05 |
Teva Pharmaceutical Industries, Ltd. |
Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
|
|
WO2006057912A2
(en)
*
|
2004-11-24 |
2006-06-01 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline orally disintegrating compositions
|
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
RS52867B
(sr)
*
|
2005-02-17 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
|
|
US7815942B2
(en)
|
2005-02-23 |
2010-10-19 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline formulations of improved content uniformity
|
|
US7491847B2
(en)
|
2005-11-17 |
2009-02-17 |
Teva Pharmaceutical Industries, Ltd. |
Methods for isolating propargylated aminoindans
|
|
US7572834B1
(en)
|
2005-12-06 |
2009-08-11 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline formulations and processes for their preparation
|
|
JP2009518433A
(ja)
|
2005-12-09 |
2009-05-07 |
イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム |
神経保護用の低用量ラドスチギルの使用
|
|
US8809310B2
(en)
|
2006-02-21 |
2014-08-19 |
Teva Pharmaceutical Industries, Ltd. |
Use of rasagiline for the treatment of multiple system atrophy
|
|
TW200744576A
(en)
|
2006-02-24 |
2007-12-16 |
Teva Pharma |
Propargylated aminoindans, processes for preparation, and uses thereof
|
|
AU2007235517B2
(en)
|
2006-04-03 |
2013-01-31 |
Teva Pharmaceutical Industries, Ltd. |
Use of rasagiline for the treatment of Restless Legs Syndrome
|
|
DE202006020710U1
(de)
|
2006-05-09 |
2009-12-31 |
Teva Pharmaceutical Industries Ltd. |
Zusammensetzungen mit Rosiglitazonmaleat
|
|
EP1892233A1
(de)
*
|
2006-08-18 |
2008-02-27 |
Ratiopharm GmbH |
Neue Salze des Wirkstoffs Rasagilin
|
|
AU2007334428B2
(en)
*
|
2006-12-14 |
2014-05-29 |
Teva Pharmaceutical Industries, Ltd. |
Crystalline solid rasagiline base
|
|
UA97382C2
(ru)
|
2006-12-14 |
2012-02-10 |
Тева Фармасьютікл Індастріз, Лтд. |
Таннат разагилина
|
|
EP1987816A1
(de)
*
|
2007-04-30 |
2008-11-05 |
Ratiopharm GmbH |
Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
|
|
US20090062400A1
(en)
*
|
2007-09-05 |
2009-03-05 |
Laurence Oron |
Method of treating glaucoma using rasagiline
|
|
US8188149B2
(en)
*
|
2007-09-17 |
2012-05-29 |
Teva Pharmaceutical Industries, Ltd. |
Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
|
|
EA201070842A1
(ru)
*
|
2008-01-11 |
2011-04-29 |
Тева Фармасьютикал Индастриз, Лтд. |
Препаративные формы разагилина, их получение и применение
|
|
US20090247537A1
(en)
*
|
2008-03-25 |
2009-10-01 |
William Dale Overfield |
Methods for preventing or treating bruxism using dopaminergic agents
|
|
WO2009122301A2
(en)
*
|
2008-03-31 |
2009-10-08 |
Actavis Group Ptc Ehf |
Rasagiline mesylate particles and process for the preparation thereof
|
|
EP2296462A4
(en)
*
|
2008-06-13 |
2011-06-15 |
Teva Pharma |
RASAGILINE FOR INFLUENCING MORBUS PARKINSON
|
|
JP2011525489A
(ja)
*
|
2008-06-19 |
2011-09-22 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラサリジン塩基の精製方法
|
|
NZ589547A
(en)
|
2008-06-19 |
2013-03-28 |
Teva Pharma |
Dried rasagiline base having a water content less than 0.5 % by weight
|
|
EP2218444A3
(en)
|
2009-01-23 |
2010-08-25 |
Teva Pharmaceutical Industries, Ltd. |
Delayed release rasagiline formulation
|
|
US20100189790A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Teva Pharmaceutical Industries, Ltd. |
Delayed release rasagiline formulation
|
|
WO2010100219A2
(en)
|
2009-03-05 |
2010-09-10 |
Sandoz Ag |
Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
|
|
PT2451771E
(pt)
|
2009-07-09 |
2014-09-19 |
Ratiopharm Gmbh |
Sais de rasagilina e suas preparações farmacêuticas
|
|
CN102048717B
(zh)
†
|
2009-10-29 |
2014-02-19 |
重庆医药工业研究院有限责任公司 |
一种稳定的雷沙吉兰组合物
|
|
WO2011087791A1
(en)
|
2009-12-22 |
2011-07-21 |
Teva Pharmaceutical Industries Ltd. |
3-keto-n-propargyl-1-aminoindan
|
|
JP5820469B2
(ja)
|
2010-04-30 |
2015-11-24 |
テイコク ファーマ ユーエスエー インコーポレーテッド |
プロピニルアミノインダンの経皮組成物
|
|
EP2389927A1
(en)
|
2010-05-30 |
2011-11-30 |
Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi |
Pharmaceutical formulations of rasagiline
|
|
RU2587330C2
(ru)
|
2010-07-27 |
2016-06-20 |
Тева Фармасьютикал Индастриз Лтд. |
Применение разагилина для лечения обонятельной дисфункции
|
|
WO2012015946A1
(en)
|
2010-07-27 |
2012-02-02 |
Teva Pharmaceutical Industries Ltd. |
Dispersion of rasagiline citrate
|
|
EP2688561B1
(en)
|
2011-03-24 |
2018-08-22 |
Teikoku Pharma USA, Inc. |
Transdermal compositions comprising an active agent layer and an active agent conversion layer
|
|
US20130089611A1
(en)
*
|
2011-10-10 |
2013-04-11 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline citramide
|
|
BR112014008555A2
(pt)
|
2011-10-10 |
2017-04-18 |
Teva Pharma |
r(+)-n-formil-propargil-aminoindano
|
|
CA2851433A1
(en)
|
2011-10-10 |
2013-04-18 |
Teva Pharmaceutical Industries Ltd. |
R(+)-n-methyl-propargyl-aminoindan
|
|
EP2776020B1
(en)
|
2011-11-09 |
2019-09-11 |
Teikoku Seiyaku Co., Ltd. |
Methods for the treatment of skin neoplasms
|
|
DE102012000786A1
(de)
|
2012-01-18 |
2013-07-18 |
Stada Arzneimittel Ag |
Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
|
|
WO2013139387A1
(en)
|
2012-03-21 |
2013-09-26 |
Synthon Bv |
Stabilized pharmaceutical compositions comprising rasagiline salts
|
|
WO2013175493A1
(en)
|
2012-04-09 |
2013-11-28 |
Cadila Healthcare Limited |
Stable oral pharmaceutical compositions
|
|
AR092168A1
(es)
|
2012-08-17 |
2015-03-25 |
Teva Pharma |
Formulaciones parenterales de rasagilina
|
|
JP6050896B2
(ja)
|
2012-11-02 |
2016-12-21 |
テイコク ファーマ ユーエスエー インコーポレーテッド |
プロピニルアミノインダン経皮組成物
|
|
ES2524865T1
(es)
*
|
2013-02-06 |
2014-12-15 |
Galenicum Health S.L. |
Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
|
|
ES2502140T1
(es)
*
|
2013-02-06 |
2014-10-02 |
Galenicum Health S.L. |
Comprimidos de liberación inmediata de rasagilina hemitartrato
|
|
CN115400090A
(zh)
*
|
2022-10-09 |
2022-11-29 |
北京新领先医药科技发展有限公司 |
一种雷沙吉兰的口崩片组合物及其制备方法
|